Results 151 to 160 of about 4,511 (199)

FOLFOX Therapy Induces Feedback Upregulation of CD44v6 through YB-1 to Maintain Stemness in Colon Initiating Cells

International Journal of Molecular Sciences, 2021
Cancer initiating cells (CICs) drive tumor formation and drug-resistance, but how they develop drug-resistance characteristics is not well understood.
Shibnath Ghatak, Roger R Markwald, Suniti Misra   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Intratumoral heterogeneity of CD44v6 in rectal cancer

Clinical and Translational Oncology, 2016
CD44v6 plays a controversial role in tumor progression and patient outcome in colorectal cancer by plenty of conflicting reports. The purpose of this study was to profile the intratumoral heterogeneity of CD44v6 in rectal cancer and investigate its role in lymph node metastasis.Sixty patients were included in this study. Immunohistochemistry for CD44v6
H-G, Liu, L, Lv, H, Shen
openaire   +2 more sources

CD44v6: a target for antibody-based cancer therapy

Cancer Immunology, Immunotherapy, 2004
The human CD44 gene encodes type 1 transmembrane glycoproteins involved in cell-cell and cell-matrix interactions. The structural heterogeneity of the gene products is caused primarily by alternative splicing of at least 10 out of 20 exons. Certain CD44 variant isoforms, in particular those containing CD44 variant domain 6 (CD44v6), have been ...
Karl-Heinz Heider
exaly   +3 more sources

CD44V6 expression in human colorectal carcinoma

Human Pathology, 1998
CD44 is an adhesion molecule involved in cell-to-cell and cell-to-matrix interactions. This transmembrane glycoprotein exists in either standard or variant forms, originated by alternative splicing. One of the isoforms (CD44V6) has been shown, in some systems, to modify the metastatic potential of tumor cells.
D, Coppola, M, Hyacinthe, L, Fu, A B, Cantor, R, Karl, J, Marcet, D L, Cooper, S V, Nicosia, H S, Cooper   +8 more
openaire   +2 more sources

CD44v6 is not relevant in colorectal tumour progression

International Journal of Colorectal Disease, 2001
There is a lack of consensus regarding the role of CD44 variants in colorectal cancer, with conflicting reports regarding their expression and correlation with prognosis. We investigated the expression and prognostic significance of CD44v6 protein in our series of colorectal tumour specimens and then analysed the pattern of CD44 variant mRNA transcript
M, Morrin, P V, Delaney
openaire   +2 more sources

CD44v6 in developing, dysplastic and malignant oral epithelia

Oral Oncology, 2003
The CD44v6 adhesion molecule has been linked to progression of various carcinomas, but its role in relation to oral-cancer development is not clear. The study was designed to determine whether CD44v6 levels were clinically significant in oral dysplasias. Twenty-nine oral dysplasias were immunostained with CD44v6 antibody on follow-up. Developing normal
Jaana Rautava, Kristiina Heikinheimo, Risto-Pekka Happonen   +2 more
exaly   +3 more sources

Significance of CD44s and CD44v6 Expression in Pancreaticobiliary Maljunction

Hepatogastroenterology, 2011
Pancreaticobiliary maljunction (PBM) is a high risk factor in biliary tract cancer. The relation of CD44s and CD44v6 expression in biliary epithelium with PBM and the carcinogenetic process was immunohistochemically examined.One hundred and seven lesions were randomly selected from gallbladders and bile ducts, which were resected from 25 patients with ...
Akihiko, Tsuchida, Yuichi, Nagakawa, Kazuhiko, Kasuya, Takaaki, Matudo, Bunso, Kyo, Yoshiaki, Suzuki, Tatsuya, Aoki, Eiichi, Sato, Toshitaka, Nagao, Takao, Itoi   +9 more
openaire   +2 more sources

CD44V6 in Gastric Carcinoma: A Marker of Tumor Progression

Applied Immunohistochemistry & Molecular Morphology, 2001
CD44 is a group of cell surface molecules involved in cell-cell and cell-matrix interactions. CD44 spliced variants (CD44V) have been found to enhance the metastatic potential of rat tumors. Tumors from the breast, colon, and thyroid express many alternatively spliced products; nonneoplastic tissues do not.
Y, Xin, A, Grace, M M, Gallagher, B T, Curran, M B, Leader, E W, Kay   +5 more
openaire   +2 more sources

Transglutaminase 2 Binds to the CD44v6 Cytoplasmic Domain to Stimulate CD44v6/ERK1/2 Signaling and Maintain an Aggressive Cancer Phenotype

Molecular Cancer Research, 2023
Abstract Transglutaminase 2 (TG2) is a key cancer cell survival protein in many cancer types. As such, efforts are underway to characterize the mechanism of TG2 action. In this study, we report that TG2 stimulates CD44v6 activity to enhance cancer cell survival via a mechanism that involves ...
Xi Chen, Gautam Adhikary, John J. Newland, Wen Xu, Jeffrey W. Keillor, David J. Weber, Richard L. Eckert   +6 more
openaire   +2 more sources

Fab-conjugated PLGA nanoparticles effectively target cancer cells expressing human CD44v6

Acta Biomaterialia, 2018
Targeting of CD44 isoforms containing exon v6 (CD44v6) represents a viable strategy for the therapy and/or early diagnosis of metastatic cancers of the epithelium (e.g. gastric and colorectal cancer).
Bruno Sarmento, Flávia Sousa, Carla Oliveira   +2 more
exaly   +2 more sources